Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6642281 | 0.86 | MAPT (0.47) | TSHRMAPTRECQLGAAALDH1A1 | |
| SCHEMBL1126496 | 0.83 | TSHR (0.37) | TSHRMAPTRECQLGAAALDH1A1 | |
| SCHEMBL165885 | 0.82 | ALDH1A1 (0.49) | MAPTGAAALDH1A1POLBKMT2A | |
| SCHEMBL873425 | 0.82 | ALDH1A1 (0.44) | MAPTGAAALDH1A1LMNARAB9A | |
| SCHEMBL17075159 | 0.81 | TSHR (0.41) | TSHRMAPTRECQLGAAALDH1A1 | |
| SCHEMBL534242 | 0.80 | CES2 (0.52) | MAPTGAAALDH1A1POLBHPGD | |
| SCHEMBL72855 | 0.80 | MAPT (0.51) | TSHRMAPTALDH1A1LMNAPOLB | |
| SCHEMBL7638404 | 0.80 | CES2 (0.52) | MAPTGAAALDH1A1POLBHPGD | |
| SCHEMBL7636018 | 0.80 | CES2 (0.52) | MAPTGAAALDH1A1POLBHPGD | |
| SCHEMBL15566866 | 0.79 | ALDH1A1 (0.40) | TSHRMAPTRECQLGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2023-08-10 | — | — | US | disclosed |
| CN-115768754-A | Dihydrooxazole and thiourea or urea derivatives that modulate NLRP3 inflammasome pathways | AC免疫有限公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2021255279-A1 | D I H YD ROOXAZO LE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2021-12-23 | — | — | WO | disclosed |
| US-20160319312-A1 | SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| US-20160319312-A1 | SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| WO-2009106599-A2 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| EP-2044059-A1 | 2,5-DISUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007141318-A1 | 2,5-DISUBSTITUTED PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160319312-A1 | SYNTHESIS METHOD FOR L-CYCLIC ALKYL AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF | ADH1B, BCAT2, BCAT1 | TSHR 3244/4885MAPT 3553/4885RECQL 1525/4885 |
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | REN, AGTR1, AGTR2 | TSHR 853/4885MAPT 4007/4885RECQL 568/4885 |
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NOD1, NLRP1 | TSHR 2430/4885MAPT 2088/4885RECQL 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.